COVID-19 Antibody Responses in Cystic Fibrosis

NAActive, not recruitingINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
COVID-19Cystic Fibrosis
Interventions
BIOLOGICAL

Blood sample

Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)

Trial Locations (9)

29684

Fondation Ildys, Roscoff

31059

Service de pneumo-allergologie pédiatrique CRCM pédiatrique CHU de Toulouse - Hôpital des Enfants, Toulouse

Service Pneumologie-Allergologie CRCM adulte Hôpital Larrey - CHU de Toulouse, Toulouse

33076

C.R.C.M. Pédiatrique (Centre de Ressources et de Compétences en Mucoviscidose) Hôpital des Enfants-Pellegrin - CHU de Bordeaux, Bordeaux

34295

Service des maladies respiratoires Hôpital Arnaud de Villeneuve - CHU de Montpellier, Montpellier

38043

Centre de Ressources et de Competences de la Mucoviscidose (Enfants) CHU Grenoble Alpes - Hôpital Couple Enfant, Grenoble

51092

Service de pédiatrie générale et spécialisée American Memorial Hospital - CHU de Reims, Reims

69677

Pneumologie, allergologie et Mucoviscidose - CRCM Lyon pédiatrie Hôpital Femme Mère Enfant /Groupement Est, Bron

76000

Maladies respiratoires, allergologie - CRCM Mixte de Rouen Hôpital Charles Nicole - CHU de Rouen, Rouen

All Listed Sponsors
collaborator

Queen's University, Belfast

OTHER

lead

Hospices Civils de Lyon

OTHER